(392 days)
No
The description focuses on the physical mechanism of gas exchange and standard sensor measurements (pressure, temperature), with no mention of AI/ML algorithms for data analysis or control.
Yes
The device is a blood oxygenator, designed to oxygenate blood and remove carbon dioxide from venous blood during cardiac surgery, which directly treats a physiological condition.
Yes.
The device measures blood pressure and temperature, which are diagnostic indicators.
No
The device description clearly details a physical, diffusion membrane oxygenator with hollow fibers made of Polymethy|pentene (PMP), connectors, and a biocompatible coating. It also mentions integrated temperature and pressure sensors, indicating hardware components. The performance studies focus on physical and mechanical properties, sterilization, and biocompatibility, not software validation.
Based on the provided text, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- Intended Use: The intended use clearly states that the device is designed to "oxygenate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass". This is a direct intervention on the blood within the body (or during a bypass procedure which is a temporary external circulation of blood from the body), not a test performed on a sample of blood or other biological material outside the body to diagnose a condition.
- Device Description: The description details how the device physically interacts with blood to perform gas exchange. It describes a "blood chamber" and "hollow fibers" where blood flows and interacts with sweep gas. This is a therapeutic/supportive function, not a diagnostic one.
- Lack of Diagnostic Language: The text does not mention any diagnostic purpose, analysis of biological samples, or the generation of diagnostic results. While it mentions measuring blood pressure and temperature, these are physiological parameters measured during the procedure, not diagnostic tests performed on a sample.
IVD devices are specifically designed to perform tests on samples taken from the human body (like blood, urine, tissue) to provide information for diagnosis, monitoring, or screening. This device's function is to modify the blood itself during a surgical procedure.
N/A
Intended Use / Indications for Use
Quantum Perfusion Blood Oxygenator ECC VT200-E1 and Quantum Perfusion Blood Oxygenator ECC VT160-E1 are diffusion membrane oxygenators, designed to oxygenate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass and to measure blood pressure and temperature during the procedure. The device is limited to 6 hours of use.
Quantum Perfusion Blood Oxygenator ECC VT200-E2 and Quantum Perfusion Blood Oxygenator ECC VT160-E2 are diffusion membrane oxygenators, designed to oxygenate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass and to measure blood pressure during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
Product codes (comma separated list FDA assigned to the subject device)
DTZ
Device Description
The Quantum Perfusion Blood Oxygenator ECC (acronym VT-E) diffusion membrane device is designed to oxygenate blood and remove carbon dioxide from venous blood during cardiac surgical procedures requiring cardiopulmonary bypass for a maximum duration of 6 hours..
Blood enters the oxygenator through the blood inlet connector, flows through a blood chamber, touching the outer surface of hollow fibers membrane; while the sweep gas flows into the hollow fiber membrane. The hollow fibers are made of Polymethylpentene (PMP). In this chamber, carbon dioxide moves from the blood to the gas compartment, while oxygen enters into the red blood cells. Then, blood exits the oxygenator with the desired level of oxygen content and saturation, and carbon dioxide content. Sweep gas composition and flow rate are used to control saturation, and oxygen and carbon dioxide content of blood at the outlet of the oxygenator.
The device is non-toxic, non-pyrogenic, sterilized by ethylene oxide and packaged in a single box.
All the device surfaces in contact with a phosphorylcholine-based biocompatible coating.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Adult patients.
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
NON-CLINICAL TESTING
In-vitro testing was performed to demonstrate the product's substantial equivalence with the predicate device and also to comply with user needs and safety and effectiveness requirements. Testing supplied in the 510(k) Notification includes biocompatibility evaluation, mechanical and performance verification, labeling and Instructions for Use (IFU), verification and validation tests.
All testing passed by meeting the established requirements set for the devices. The following data were provided:
-Performance tests, according to applicable special controls according to ISO 7199, 21 CFR §870.4350 and "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff", dated November 13, 2000:
- Operating priming volume;
- Device pressure Drop;
- Gas Transfer Performances;
- Mechanical Blood Cell Damage;
- Ease of Prime and Air handling;
- Filtration efficiency;
- Temperature probe and Pressure sensor verification;
- Mechanical Integrity;
- Mechanical resistance of connectors;
- Coating coverage and durability.
- Evaluation of product shelf life, including product's sterility according to EP/UPS requirements;
- Validation of the EtO Sterilization process, according to ISO 11135:2014 [Recognition Nr.: 14-452];
- Packaging Validation tests according to ISO 11607-1:2019 [Recognition Nr.: 14-530];
- Biocompatibility of the finished product, according to International Standard ISO 10993-1:2018 [Recognition Nr. 2-258] and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process".
Animal Study
No animal studies have been performed except for mandatory biocompatibility tests according to International Standard ISO 10993-1:2018 [Recognition Nr. 2-258] and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process".
CLINICAL TESTING
No clinical data have been included in the current Traditional 510(k) submission to support substantial equivalence to legally marketed predicate devices.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 870.4350 Cardiopulmonary bypass oxygenator.
(a)
Identification. A cardiopulmonary bypass oxygenator is a device used to exchange gases between blood and a gaseous environment to satisfy the gas exchange needs of a patient during open-heart surgery.(b)
Classification. Class II (special controls). The special control for this device is the FDA guidance document entitled “Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions.”
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the seal of the Department of Health & Human Services. To the right of the seal is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, and the word "ADMINISTRATION" in a smaller font size below.
December 17, 2021
Qura S.r.1. Raffaella Tommasini QA&RA Director Via di Mezzo, 23 Mirandola, Modena 41037 Italy
Re: K203424
Trade/Device Name: Quantum Perfusion Blood Oxygenator ECC VT200-E1, Quantum Perfusion Blood Oxygenator ECC VT200-E2, Quantum Perfusion Blood Oxygenator ECC VT160-E1, Quantum Perfusion Blood Oxygenator ECC VT160-E2 Regulation Number: 21 CFR 870.4350 Regulation Name: Cardiopulmonary Bypass Oxygenator Regulatory Class: Class II Product Code: DTZ Dated: November 18, 2021 Received: November 22, 2021
Dear Raffaella Tommasini:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal
1
statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
Sincerely,
Nicole Gillette Assistant Director DHT2B: Division of Circulatory Support, Structural and Vascular Devices OHT2: Office of Cardiovascular Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
2
Indications for Use
510(k) Number (if known) K203424
Device Name
Quantum Perfusion Blood Oxygenator ECC VT200-E2
Indications for Use (Describe)
Quantum Perfusion Blood Oxygenator ECC VT200-E2 is a diffusion membrane oxygenator, designate and remove carbon dioxide from venous blood during cardiopulmonary bypass and to measure blood pressure during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
3
Indications for Use
510(k) Number (if known) K203424
Device Name
Quantum Perfusion Blood Oxygenator ECC VT200-E1
Indications for Use (Describe)
Quantum Perfusion Blood Oxygenator ECC VT200-E1 is a diffusion membrane oxygenator, designate and remove carbon dioxide from venous blood during cardiopulmonary bypass and to measure blood pressure and temperature during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
er aspect
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
4
Indications for Use
510(k) Number (if known) K203424
Device Name
Quantum Perfusion Blood Oxygenator ECC VT160-E2
Indications for Use (Describe)
Quantum Perfusion Blood Oxygenator ECC VT160-E2 is a diffusion membrane oxygenator, designate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass and to measure blood pressure during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
Form Approved: OMB No. 0910-0120
Expiration Date: 06/30/2023
See PRA Statement below.
PSC Publishing Services (301) 443-6740 EF
5
Indications for Use
510(k) Number (if known) K203424
Device Name
Quantum Perfusion Blood Oxygenator ECC VT160-E1
Indications for Use (Describe)
Quantum Perfusion Blood Oxygenator ECC VT160-E1 is a diffusion membrane oxygenator, designate and remove carbon dioxide from venous blood during cardiopulmonary bypass and to measure blood pressure and temperature during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
_ Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
ed to oxygenate and
Form Approved: OMB No. 0910-0120 Expiration Date: 06/30/2023 See PRA Statement below.
6
510(K) SUMMARY
SUBMITTER
| Submitter Name: | Qura S.r.l. |
|---|---|
| Submitter Address: | Via di Mezzo, 23 41037 Mirandola (MO) Italy |
| Contact Person: | Raffaella Tommasini, QA&RA Director – Qura s.r.l. |
| Phone: | +39 0535 1803050 |
| e-mail: | raffaella.tommasini@quramed.com |
| Fax: | +39 0535 1803051 |
| Date Summary Prepared: | December 17th, 2021 |
| II. DEVICE | Quantum Perfusion Blood Oxygenator ECC VT200-E1, Quantum Perfusion Blood
Oxygenator ECC VT200-E2, Quantum Perfusion Blood Oxygenator ECC VT160-E1
Quantum Perfusion Blood Oxygenator ECC VT160-E2 |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Proprietary Name: | |
| Common Name: | Blood Oxygenator |
| Common Name: | Blood Oxygenator |
| Classification Name: | Oxygenator, Cardiopulmonary Bypass |
| Regulatory Class: | II |
| Product Code: | DTZ |
| Panel: | Cardiovascular Devices, Office of Health Technology 2 (OHT2) / Division of Health
Technology 2 B (Circulatory Support, Structural and Vascular Devices) |
PREDICATE AND REFERENCE DEVICES ==
| Predicate device: | |
|---|---|
| Trade Name: | QUADROX-iD Adult |
| Registered Establishment Name: | MAQUET CARDIOPULMONARY AG |
| Regulation Number: | 870.4350 |
| Regulation Name: | Cardiopulmonary Bypass Oxygenator |
| Regulatory Class: | II |
| Product Code: | DTZ |
| 510(k) Number | K150267 |
Reference device:
| Trade Name: | EOS PMP |
|---|---|
| Registered Establishment Name: | Sorin Group Italia S.r.l. |
| Regulation Number: | 870.4350 |
| Regulation Name: | Cardiopulmonary Bypass Oxygenator |
| Regulatory Class: | II |
| Product Code: | DTZ |
| 510(k) Number | K150489 |
7
IV. DEVICE DESCRIPTION
The Quantum Perfusion Blood Oxygenator ECC (acronym VT-E) diffusion membrane device is designed to oxygenate blood and remove carbon dioxide from venous blood during cardiac surgical procedures requiring cardiopulmonary bypass for a maximum duration of 6 hours..
Blood enters the oxygenator through the blood inlet connector, flows through a blood chamber, touching the outer surface of hollow fibers membrane; while the sweep gas flows into the hollow fiber membrane. The hollow fibers are made of Polymethy|pentene (PMP). In this chamber, carbon dioxide moves from the blood to the gas compartment, while oxygen enters into the red blood cells. Then, blood exits the oxygenator with the desired level of oxygen content and saturation, and carbon dioxide content. Sweep gas composition and flow rate are used to control saturation, and oxygen and carbon dioxide content of blood at the outlet of the oxygenator.
The device is non-toxic, non-pyrogenic, sterilized by ethylene oxide and packaged in a single box.
All the device surfaces in contact with a phosphorylcholine-based biocompatible coating.
| CODE | ||||
|---|---|---|---|---|
| Characteristics | VT200-E1 | VT200-E2 | VT160-E1 | VT160-E2 |
| Blood contact materials | Tritan copolyester | |||
| Polymethylpentene (PMP) | ||||
| Polyurethane (PU) | ||||
| Coating: phosphorylcholine | ||||
| Maximum operating pressure - blood side | 760 mmHg / 100 kPa / 1 bar / 14.5 psi | |||
| Static priming volume (ml) | 195 | 160 | ||
| Exchange surface area (m²) | 1.75 | 1.45 | ||
| Blood flow (l/min) | 1-7 | 0.5-5 | ||
| Maximum gas flow (l/min) | 10 | 10 | ||
| Connections - blood side (IN/OUT) | 3/8" (9.525mm) | 3/8" (9.525mm) | ||
| Arterial sampling | Luer Lock | Luer Lock | ||
| Purge line | Luer Lock | Luer Lock | ||
| Connections - gas side | ||||
| IN | CPC APC profile | CPC APC profile | ||
| Connections - gas side | ||||
| OUT | 1/4" (6.35mm) and Luer Lock | 1/4" (6.35mm) and Luer Lock | ||
| Temperature probe - Blood OUT | YSI 400 | NA | YSI 400 | NA |
| Blood OUT pressure sensor - Range | -200 to 600 mmHg / -27 to 80 KPa / -0.27 to 0.8 bar / -3.8 to 11.6 psi |
Significant physical and performance characteristics:
Table 5-1 —Main characteristics
Additional information have been provided in Section 10 of K203424 submission.
8
INTENDED USE / INDICATIONS FOR USE V.
Quantum Perfusion Blood Oxygenator ECC VT200-E1 and Quantum Perfusion Blood Oxygenator ECC VT160-E1 are diffusion membrane oxygenators, designed to oxygenate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass and to measure blood pressure and temperature during the procedure. The device is limited to 6 hours of use.
Quantum Perfusion Blood Oxygenator ECC VT200-E2 and Quantum Perfusion Blood Oxygenator ECC VT160-E2 are diffusion membrane oxygenators, designed to oxygenate and remove carbon dioxide from venous blood during cardiac surgery requiring cardiopulmonary bypass and to measure blood pressure during the procedure. The device is limited to 6 hours of use.
Devices are intended for adult patients.
VI. COMPARISON OF TECHNOLOGICAL CHARACTERISTICS WITH THE PREDICATE DEVICE
An extensive and complete comparison between Quantum Perfusion Blood Oxygenator ECC (all variants) and the predicate device has been conducted. Based on the safety, performance data, technological characteristics, and the indications for use of the predicate device:
-
l Quantum Perfusion Blood Oxygenator ECC (all variants) are considered substantially equivalent to the legally marketed predicate device QUADROX-iD Adult Oxygenator (K150267) since the intended use, main blood-contact materials and technological characteristics are the same.
In addition, in terms of performance: -
. VT200-E1 and VT200-E2 devices are considered substantially equivalent to the legally marketed predicate device QUADROX-iD Adult Oxygenator (K150267).
-
. VT160-E1 and VT160-E2 devices are considered substantially equivalent to the legally marketed reference predicate device EOS-PMP (K150489).
A summary of the technological characteristics of Quantum Perfusion Blood Oxygenator ECC to those of the predicate/reference device has been given in table below.
Additional information have been provided in Section 12 of K203424 submission.
9
| Device | Proposed Device - Quantum
Perfusion Blood Oxygenator
ECC | Predicate Device –
Maquet Quadrox-iD Adult
Oxygenator | Reference Predicate Device
– Sorin Group Italia EOS
PMP |
|-------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Name | Quantum Perfusion Blood
Oxygenator ECC VT200-E1
Quantum Perfusion Blood
Oxygenator ECC VT200-E2 | QUADROX-iD Adult | EOS PMP |
| | Quantum Perfusion Blood
Oxygenator ECC VT160-E1
Quantum Perfusion Blood
Oxygenator ECC VT160-E2 | | |
| 510(k) Number | K203424 | K150267 | K150489 |
| Regulation # | | 870.4350 | |
| Regulation Name | Cardiopulmonary Bypass Oxygenator | | |
| Product Code | DTZ | | |
| Classification | II | | |
| Indication for Use | Quantum Perfusion Blood
Oxygenator ECC VT200-E1 and
Quantum Perfusion Blood
Oxygenator ECC VT160-E1 are
diffusion membrane
oxygenators, designed to
oxygenate and remove carbon
dioxide from venous blood
blood during cardiac surgery
requiring cardiopulmonary
bypass and to measure blood
pressure and temperature
during the procedure. The
device is limited to 6 hours of
use.
Quantum Perfusion Blood
Oxygenator ECC VT200-E2 and
Quantum Perfusion Blood
Oxygenator ECC VT160-E2 are
diffusion membrane
oxygenators, designed to
oxygenate and remove carbon
dioxide from venous blood
during cardiac surgery requiring
cardiopulmonary bypass and to
measure blood pressure during
the procedure. The device is
limited to 6 hours of use.
Devices are intended for adult
patients. | The QUADROX-iD Adult
oxygenator is intended for
use in an extracorporeal
circulation during
cardiopulmonary bypass in
cardiac surgery. Within the
specified flow rate range,
the device oxygenates the
blood, removes carbon
dioxide from the blood and
regulates the blood
temperature. The
application duration is
limited to 6 hours.
Responsibility for deciding
whether to use an
oxygenator rests solely
with the attending
physician. | The device is intended for use
in patients who undergo
cardiopulmonary bypass
surgery requiring
extracorporeal circulation
with a maximum blood flow
rate of 5 liters/minute. It
provides oxygenation and
carbon dioxide removal from
venous blood. The integrated
heat exchanger provides
blood temperature control
and allows the use of
hypothermia or aids in the
maintenance of
normothermia during
surgery. The device is
intended to be used for 6
hours or less. |
| Main Contacting
Materials | Fiber: Polymethylpentene
(PMP)
Coating: Phosphorylcholine
Housing: Tritan
Sensor: Polycarbonate and
silicone based protective gel | Fiber: Polymethylpentene
(PMP)
Coating: Softline (synthetic
polymer-based coating)
Housing: Polycarbonate
(PC) | Fiber: Polymethylpentene
(PMP)
Coating: Phosphorylcholine
Housing: Polycarbonate
Heat exchanger: Stainless
steel |
| Device | Proposed Device – Quantum
Perfusion Blood Oxygenator
ECC | Predicate Device –
Maquet Quadrox-iD Adult
Oxygenator | Reference Predicate Device
– Sorin Group Italia EOS
PMP |
| | | Heat exchanger:
thermoplastic
polyurethane (TPU) | |
| Blood side Connector
Type | | 3/8" (9.525mm) | |
| Max flow rate [l/min] | | | |
| VT200-E1, VT200-E2 | 7 | 7 | |
| VT160-E1, VT60-E2 | 5 | | 5 |
| Exchange surface [m²] | | | |
| VT200-E1, VT200-E2 | 1.75 | 1.8 | |
| VT160-E1, VT60-E2 | 1.45 | | 1.2 |
| Static Priming
Volume [ml] | 195 | 215 | |
| | 160 | | 150 |
| Presence of sensor | Pressure sensors located
integrated in the blood out
connector. | Not present | Not present |
| Single-use | Yes | Yes | |
| Sterile Condition | EtO Sterile | EtO Sterile | |
10
Table 5-2 – Comparative Data
11
VIII. PERFORMANCE DATA
NON-CLINICAL TESTING
In-vitro testing was performed to demonstrate the product's substantial equivalence with the predicate device and also to comply with user needs and safety and effectiveness requirements. Testing supplied in the 510(k) Notification includes biocompatibility evaluation, mechanical and performance verification, labeling and Instructions for Use (IFU), verification and validation tests.
All testing passed by meeting the established requirements set for the devices. The following data were provided:
- -Performance tests, according to applicable special controls according to ISO 7199, 21 CFR §870.4350 and "Guidance for Cardiopulmonary Bypass Oxygenators 510(k) Submissions; Final Guidance for Industry and FDA Staff", dated November 13, 2000:
- o Operating priming volume;
- O Device pressure Drop;
- Gas Transfer Performances; O
- O Mechanical Blood Cell Damage;
- Ease of Prime and Air handling; O
- O Filtration efficiency;
- O Temperature probe and Pressure sensor verification;
- Mechanical Integrity; O
- o Mechanical resistance of connectors;
- O Coating coverage and durability.
- Evaluation of product shelf life, including product's sterility according to EP/UPS requirements; -
- -Validation of the EtO Sterilization process, according to ISO 11135:2014 [Recognition Nr.: 14-452];
- -Packaging Validation tests according to ISO 11607-1:2019 [Recognition Nr.: 14-530];
- -Biocompatibility of the finished product, according to International Standard ISO 10993-1:2018 [Recognition Nr. 2-258] and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process".
Animal Study
No animal studies have been performed except for mandatory biocompatibility tests according to International Standard ISO 10993-1:2018 |Recognition Nr. 2-258| and FDA Guidance "Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process".
CLINICAL TESTING
No clinical data have been included in the current Traditional 510(k) submission to support substantial equivalence to legally marketed predicate devices.
VIII. CONCLUSIONS
Based on the indications for use, main technological characteristics and results of non-clinical testing, the subject devices have been demonstrated to be appropriate for their intended use and are considered substantially equivalent to legally marketed predicate (K150267) and reference (K150489) devices.